Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

heumann pharma gmbh & co. generica kg (8120809) - rizatriptanbenzoat - tablette - rizatriptanbenzoat (28024) 7,265 milligramm

Europska Unija - njemački - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - brexpiprazole - schizophrenie - psycholeptika - behandlung von schizophrenie.

Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ucb pharma gmbh - levocetirizindihydrochlorid - filmtablette - levocetirizindihydrochlorid 5.mg

Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ucb pharma gmbh - levocetirizindihydrochlorid - tropfen zum einnehmen, lösung - levocetirizindihydrochlorid 5.mg

Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ucb pharma gmbh - levocetirizindihydrochlorid - tropfen zum einnehmen, lösung - levocetirizindihydrochlorid 5.mg

Austrija - njemački - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ucb pharma gmbh - levocetirizin dihydrochlorid - levocetirizin

Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bluefish pharmaceuticals ab (publ) (8093076) - levocetirizindihydrochlorid - filmtablette - teil 1 - filmtablette; levocetirizindihydrochlorid (31082) 5 milligramm

Europska Unija - njemački - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europska Unija - njemački - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - selektive immunsuppressiva - colitis colitisentyvio ist indiziert für die behandlung von erwachsenen patienten mit mittelschwerer bis schwerer aktiver colitis ulcerosa, die unzureichend mit, verloren, antwort, oder waren intolerant entweder konventionelle therapie oder tumor-nekrose-faktor alpha (tnfa) - antagonisten. morbus crohn diseaseentyvio ist indiziert für die behandlung von erwachsenen patienten mit mäßig bis schwer aktivem morbus crohn, die haben eine unzureichende antwort mit, verloren, antwort, oder waren intolerant entweder konventionelle therapie oder tumor-nekrose-faktor alpha (tnfa) - antagonisten. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Njemačka - njemački - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - levocetirizindihydrochlorid - filmtablette - teil 1 - filmtablette; levocetirizindihydrochlorid (31082) 5 milligramm